Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
This study of increasing Coriolus versicolor supplementation (4.5 grams per day to 13.0 grams per day over a 90 day period) measures the impact of such supplementation on telomerase activity, interleukin 5, interleukin 12 and Tumour Necrosis Factor Beta over 120 days. Results were a significant decrease in teleomerase and interleukin-12 activity, followed by a significant increase in interleukin-5 activity within 120 days.
To contact Dr. Julian Kenyon (MD MB ChB)
Dove Clinic for Integrated Medicine
97 Harley Street
London W1G 6AG
United Kingdom
Tel:44-207-487-4442
Email: doveclinic@ukonline.co.uk
http://www.doveclinic.com
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF
Clinical articles
-
Neuroprotective Effects of Mushroom Biomass Digestive Fractions and Gut Microbiota Metabolites in Microglial and Caenorhabditis elegans Models of Neurodegeneration
Helena Araújo-Rodrigues 1,2 , Lidia Garzón-García 3 Freni K. Tavaria 1 , Celestino Santos-Buelga 3 , Ana Sofia Salsinha 1 , João Bettencourt Relvas 2,4 , Ana M.González-Paramás 3 and Manuela E.Pintado1,* -
Characterization of Children with Intellectual Disabilities and Relevance of Mushroom Hericium Biomass Supplement to Neurocognitive Behavior
Plamen Dimitrov 1,*, Alexandra Petrova 2, Victoria Bell 3,4 and Tito Fernandes 5 -
Bioaccessibility and Bioavailability of Bioactive Compounds from Mushroom Biomass Following in vitro Gastrointestinal Digestion presented at the CIPCA 2025 X International Conference on Food Proteins and Collides June 16-18, 2025 in Porto Portugal.
Helena Araújo-Rodrigues, Manuela Machado, João B. Relvas , Freni K. Tavaria, Manuela Pintado -
Neuroprotective Effects of Mushroom Biomass: Impact of Serum-Available and Gut Microbiota Metabolites in Caenorhabditis elegans Models of Alzheimer’s Disease. Presented on June 13th at the XXIII EURO FOODCHEM 2025 Conference in Bratislava, Slovakia
Helena Araújo-Rodrigues,Lidia Garzón-García, João B. Relvas, Freni K. Tavaria, Celestino Santos-Buelga, Ana M. González-Paramás, and Manuela E. Pintado